APP-related brain and vascular amyloidosis
MONDO:1060190A hereditary amyloidosis characterized by a spectrum of neurodegenerative and neurovascular phenotypes caused by pathogenic variant in the APP gene, resulting in an abnormal clearance of amyloid peptides, either by overproduction and decreased clearance of amyloid peptides, with deposition of amyloid in plaques and blood vessel walls. Affected individuals may present with progressive cognitive decline, cerebral vascular amyloidosis with white matter changes, and stroke with or without hemorrhage.
Also known as: APP-related brain and vascular amyloidosis
18 clinical trials for this condition and its sub-types, 0 tagged with APP-related brain and vascular amyloidosis itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of APP-related brain and vascular amyloidosis
-
Alzheimer disease type 1 4 trials
-
Cerebral amyloid angiopathy, APP-related 0 trials · 1 incl. sub-types
6 sub-types
- ABeta amyloidosis, dutch type 1 trial
- ABeta amyloidosis, Arctic type 0 trials
- ABeta amyloidosis, Iowa type 0 trials
- ABeta amyloidosis, Italian type 0 trials
- ABetaA21G amyloidosis 0 trials
- ABetaL34V amyloidosis 0 trials
-
Can deep sleep or nerve stimulation flush toxic proteins from the brain?
Disease control By invitation onlyThis Phase 2 trial tests whether a sleep-deepening drug (lower-sodium oxybate) or a nerve-stimulating device (non-invasive vagus nerve stimulation), or both, can help clear amyloid-beta protein from the brain in people with cerebral amyloid angiopathy (CAA). Sixty participants wi…
Phase 2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
Could sound waves help Alzheimer's drugs work better?
Disease control OngoingThis study tests whether using focused ultrasound to temporarily open the blood-brain barrier can safely help standard antibody therapy reach the brain in people with mild Alzheimer's or mild cognitive impairment. About 15 participants will receive the combined treatment. The goa…
Early phase 1 • Sponsor: Ali Rezai • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC